Literature DB >> 28314318

Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer.

In Hee Lee1, Soyoon Hwang1, Soo Jung Lee1, Byung Woog Kang1, Dongwon Baek1, Hye Jin Kim2, Su Yeon Park2, Jun Seok Park2, Gyu Seog Choi2, Jae Chul Kim3, Seung Hyun Cho4, Jong Gwang Kim5.   

Abstract

AIM: Systemic inflammatory response (SIR) has been reported to be an important determinant of disease progression and survival in patients with colorectal cancer. This study investigated the prognostic relevance of changes in the platelet count on survival and the predictive value of changes in platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) on the pathological tumor response to preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (LARC). PATIENTS AND METHODS: From 2006 to 2015, 291 consecutive patients with LARC who were treated with preoperative CRT followed by curative surgery at the Kyungpook National University Medical Center (Daegu, Korea) were retrospectively analyzed. A cut-off value of 370×103/μl for the platelet count was used and a PLR ≥235 was defined as high. Any change in the PLR or NLR was calculated based on subtracting the pre-CRT PLR or NLR from the post-CRT values.
RESULTS: A total of 17.5% patients had stage II and 82.5% had stage III LARC. Initially high NLR and PLR were significantly associated with poor clinical outcomes. Patients who maintained a high platelet count after CRT also had an advanced pathological stage (p=0.028), low pathological complete response rate (p=0.048), and high relapse rate (p=0.021). For patients with an initially low PLR, the multiple logistic regression analysis revealed that a high PLR change (odds ratio (OR)=2.301, 95% confidence interval (CI)=1.269-4.174; p=0.006) and clinical stage II compared to stage III (OR=1.878, 95% CI=1.231-2.865; p=0.003) were significant independent markers predictive of a good response to CRT.
CONCLUSION: The present results suggest that platelet and PLR change after preoperative CRT, along with the initial platelet count, can be used as prognostic and predictive markers for the oncological outcomes in patients with LARC. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Rectal cancer; chemoradiotherapy; platelet/lymphocyte ratio; predictive marker

Mesh:

Year:  2017        PMID: 28314318     DOI: 10.21873/anticanres.11470

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer.

Authors:  Alexander D Sherry; Rie von Eyben; Neil B Newman; Paulina Gutkin; Ingrid Mayer; Kathleen Horst; A Bapsi Chakravarthy; Marjan Rafat
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-12-03       Impact factor: 7.038

2.  Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study.

Authors:  Joo Ho Lee; Byung-Hee Kang; Changhoon Song; Sung-Bum Kang; Hye Seung Lee; Keun-Wook Lee; Eui Kyu Chie; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Prognostic value of platelet-to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis.

Authors:  Yuming Long; Yingtian Zhang; Liwei Ni; Xuya Yuan; Yuanliang Liu; Jialong Tao; Yusong Zhang
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

4.  Poor nutrition and sarcopenia are related to systemic inflammatory response in patients with rectal cancer undergoing preoperative chemoradiotherapy.

Authors:  Shinya Abe; Hiroaki Nozawa; Kazushige Kawai; Kazuhito Sasaki; Koji Murono; Shigenobu Emoto; Junko Kishikawa; Tsuyoshi Ozawa; Yuichiro Yokoyama; Yuzo Nagai; Hiroyuki Anzai; Hirofumi Sonoda; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2021-10-11       Impact factor: 2.571

5.  The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis.

Authors:  Xuan Li; Danian Dai; Bo Chen; Hailin Tang; Xiaoming Xie; Weidong Wei
Journal:  J Cancer       Date:  2018-02-12       Impact factor: 4.207

6.  Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.

Authors:  Claudio Belluco; Marco Forlin; Paolo Delrio; Daniela Rega; Maurizio Degiuli; Silvia Sofia; Matteo Olivieri; Salvatore Pucciarelli; Matteo Zuin; Giovanni De Manzoni; Alberto Di Leo; Stefano Scabini; Luigi Zorcolo; Angelo Restivo
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

7.  Prognostic impact of persistent lower neutrophil-to-lymphocyte ratio during preoperative chemoradiotherapy in locally advanced rectal cancer patients: A propensity score matching analysis.

Authors:  Yoon Jin Cha; Eun Jung Park; Seung Hyuk Baik; Kang Young Lee; Jeonghyun Kang
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

8.  Meta-Analysis on the Neutrophil-Lymphocyte Ratio in Rectal Cancer Treated With Preoperative Chemoradiotherapy: Prognostic Value of Pre- and Post-Chemoradiotherapy Neutrophil-Lymphocyte Ratio.

Authors:  Soo Jin Lee; Kyubo Kim; Hae Jin Park
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

9.  The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer.

Authors:  Yu Fu; Xiaowan Chen; Yongxi Song; Xuanzhang Huang; Quan Chen; Xinger Lv; Peng Gao; Zhenning Wang
Journal:  BMC Cancer       Date:  2021-07-08       Impact factor: 4.430

10.  A comparison of the prognostic value of composite ratios and cumulative scores in patients with operable rectal cancer.

Authors:  Ross D Dolan; Muhammed Alwahid; Stephen T McSorley; James H Park; Richard P Stevenson; Campbell S Roxburgh; Paul G Horgan; Donald C McMillan
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.